Targeted alpha therapy with 213Bi
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
APOSTOLIDIS Christos;
2011-11-11
Bentham Science Publishers Ltd.
JRC64087
1874-4710,
http://www.benthamdirect.org/pages/content.php?CRP/2011/00000004/00000004/0003CRP.SGM,
https://publications.jrc.ec.europa.eu/repository/handle/JRC64087,
10.2174/1874471011104040295,
Additional supporting files
| File name | Description | File type | |
|---|
